Historically, small molecule drugs have been precisely designed down to the atomic scale. Considering their relatively large complex structures, nanomedicines have lagged behind. Researchers argue ...

Historically, the vast majority of pharmaceutical drugs have been meticulously designed down to the atomic level. The ...

This new lipid nanoparticle production system developed by Shin-Etsu Chemical and Hokkaido University is capable of small-batch and mass production ...

Advancements in mRNA vaccine technology are reshaping medicine, addressing challenges and expanding applications from ...

Scientists in The Wistar Institute lab of David B. Weiner, Ph.D., have described a next-generation vaccination technology that combines plasmid DNA with a lipid nanoparticle (LNP) delivery system.

Shin-Etsu Chemical Co., Ltd. (Head Office: Tokyo; President: Yasuhiko Saitoh; hereinafter, "Shin-Etsu Chemical") and Hokkaido University (Location ...

Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, announced that Randall ...

Marama Labs has launched its CloudSpec instrument for nanomedicine development, which is expected to cut time and speed up ...

Q4 2024 Earnings Call Transcript April 10, 2025 CureVac N.V. misses on earnings expectations. Reported EPS is $-0.16564 EPS, ...

Effective treatments for ARVC are lacking. Whereas mRNA-based therapies have shown efficacy in humans, their therapeutic potential for inherited cardiomyopathies remains unclear. A novel insertion ...

The global vaccine CDMO market is set to witness a growth rate of 8% in the next 5 years. Increasing demand for vaccines, ...